2023
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium
POULIMENEAS, Dimitrios, Markela KONIORDOU, Dimitra KOUSI, Christina MERAKOU, Ioannis KOPSIDAS et. al.Základní údaje
Originální název
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium
Autoři
POULIMENEAS, Dimitrios, Markela KONIORDOU, Dimitra KOUSI, Christina MERAKOU, Ioannis KOPSIDAS, Grammatiki Christina TSOPELA, Christos D ARGYROPOULOS, Sophia C THEMISTOCLEOUS, George SHIAMAKKIDES, Marinos CONSTANTINOU, Alexandra ALEXANDROU, Evgenia NOULA, Andria NEARCHOU, Jon SALMANTON-GARCÍA, Fiona A STEWART, Sarah HERINGER, Kerstin ALBUS, Elena ÁLVAREZ-BARCO, Alan MACKEN, Romina Di MARZO, Catarina LUIS, Paula VALLE-SIMÓN, Helena H ASKLING, Margot HELLEMANS, Orly SPIVAK, Ruth Joanna DAVIS, Anna Maria AZZINI, Imre BARTA, Lenka SOUČKOVÁ (203 Česká republika, domácí), Ligita JANCORIENE, Murat AKOVA, Patrick W G MALLON, Ole F OLESEN, Jesus FRIAS-INIESTA, Pierre van DAMME, Krisztina TÓTH, Miriam COHEN-KANDLI, Rebecca Jane COX, Petr HUSA (203 Česká republika, domácí), Pontus NAUCLÉR, Laura MARQUES, Jordi OCHANDO, Evelina TACCONELLI, Markus ZEITLINGER, Oliver A CORNELY, Zoi Dorothea PANA a Theoklis E ZAOUTIS
Vydání
Vaccines, Basel, MDPI, 2023, 2076-393X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30303 Infectious Diseases
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 7.800 v roce 2022
Kód RIV
RIV/00216224:14110/23:00132500
Organizační jednotka
Lékařská fakulta
UT WoS
001131427300001
Klíčová slova anglicky
barriers; COVID-19; Europe; pandemic preparedness; SARS-CoV-2; vaccinations; vaccine education; vaccine trials
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 27. 2. 2024 14:13, Mgr. Tereza Miškechová
Anotace
V originále
Underserved and hard-to-reach population groups are under-represented in vaccine trials. Thus, we aimed to identify the challenges of vaccine trial participation of these groups in member countries of the VACCELERATE network. Seventeen National Coordinators (NC), each representing their respective country (15 European countries, Israel, and Turkey), completed an online survey. From 15 eligible groups, those that were more frequently declared underserved/hard-to-reach in vaccine research were ethnic minorities (76.5%), persons experiencing homelessness (70.6%), illegal workers and refugees (64.7%, each). When prioritization for education on vaccine trials was considered, ethnic groups, migrants, and immigrants (5/17, 29.4%) were the groups most frequently identified by the NC as top targets. The most prominent barriers in vaccine trial participation affecting all groups were low levels of health literacy, reluctance to participate in trials due to engagement level, and low levels of trust in vaccines/vaccinations. This study highlighted population groups considered underserved/hard-to-reach in countries contained within the European region, and the respective barriers these groups face when participating in clinical studies. Our findings aid with the design of tailored interventions (within—and across—countries of the European region) and with the development of strategies to overcome major barriers in phase 2 and phase 3 vaccine trial participation.
Návaznosti
90249, velká výzkumná infrastruktura |
|